摘要
目的观察贝伐珠单抗联合AP化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效。方法回顾性选取2019年6月—2022年6月铜陵市立医院收治的晚期NSCLC患者80例,依据化疗方案不同分为AP组和联合化疗组,各40例。AP组给予培美曲塞二钠和顺铂;联合化疗组在AP组基础上给予贝伐珠单抗注射液,2组均以3周为1个周期,共治疗2个化疗周期。比较2组近期疗效,化疗前与化疗2个周期后血清肿瘤标志物、T淋巴细胞亚群、视觉模拟评分法(VAS)评分、EORTC生命质量测定量表评分,中位生存时间、无进展生存时间及不良反应。结果联合化疗组客观缓解率为47.50%,高于AP组的25.00%(χ^(2)=4.381,P=0.036)。化疗2个周期后,2组血清癌胚抗原、糖类抗原125、细胞角蛋白19片段抗原21-1、神经元特异性烯醇化酶水平、CD8^(+)低于化疗前,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于化疗前,且联合化疗组低/高于AP组(P<0.01);2组VAS评分低于化疗前,认知功能、社会功能、情绪功能评分高于化疗前,且联合化疗组低/高于AP组(P<0.01)。联合化疗组中位生存时间、无进展生存时间长于AP组(P<0.01)。AP组与联合化疗组不良反应发生率比较,差异无统计学意义(P>0.05)。结论贝伐珠单抗联合AP化疗方案治疗晚期NSCLC患者的临床效果显著,可有效抑制病情进展,减轻疼痛,提高患者生活质量,可延长患者生存时间,且并不会增加不良反应。
Objective To observe the clinical effect of the combination of bevacizumab and AP chemotherapy regimen in the treatment of advanced NSCLC and the impact on tumor markers.Methods A total of 80 cases of advanced NSCLC patients admitted to Tongling Municipal Hospital from June 2019 to June 2022 were retrospectively selected,and they were divided into the AP group and the combination chemotherapy group by different chemotherapy regimens,40 cases in each group.In the AP group,patients were given pemetrexed disodium and cisplatin;in the combination chemotherapy group,patients were given bevacizumab injection on the basis of the AP group,and the two groups were taken 3 weeks as a chemotherapy cycle,with a total of 2 cycles of chemotherapy.Recent efficacy,tumor markers,T lymphocyte subsets,VAS score,EORTC QLQ-C30 score before and after 2 cycles of chemotherapy,median survival time,progression-free survival time,and adverse reactions were compared between the two groups.Results The objective remission rate in the combination chemotherapy group was 47.50%,which was higher than 25.00%in the AP group(χ^(2)=4.381,P=0.036).After 2 cycles of chemotherapy,serum levels of carcinoembryonic antigen,carbohydrate antigen 125,cytokeratin 19 fragment antigen 21-1,neuron specific enolase,and CD8^(+)in the two groups were lower than those before chemotherapy,and CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher than those before chemotherapy,and the indexes of the combination chemotherapy group were lower/higher than those in the AP group(P<0.01);VAS score of the two groups was lower than that before chemotherapy,and scores of cognitive function,social function and emotional function were higher than those before chemotherapy,and the combination chemotherapy group were lower/higher than those in the AP group(P<0.01).Median survival time and progression-free survival time in the combination chemotherapy group were longer than those in the AP group(P<0.01).There was no statistically significant difference in the total incidence of adverse rea
作者
刘勇
杨刚
王静静
LIU Yong;YANG Gang;WANG Jingjing(不详;Department of Oncology,Tongling Municipal Hospital,Anhui Province,Tongling 244000,China)
出处
《临床合理用药杂志》
2024年第12期5-8,共4页
Chinese Journal of Clinical Rational Drug Use
